semaglutide weight loss medication Novo Nordisk's weight-loss pill wins FDA approval Semaglutide: Side effects, use for

Pyrshev et al

Please note: Silver and gold wallet credit does not apply to take-home vials, but the 15% member discount does

569, no

[DOI] [PMC free article] [PubMed] [Google Scholar] 251.Suzuki K., Kim K.S., Bae Y.H

The tablets for skin help promote long-term skin health by reducing oxidative stress

The studys methodology and findings revealed data points: Among 710 type 2 diabetes patients, 17 semaglutide users developed NAION versus only 6 non-users, despite similar baseline characteristics In the weight loss cohort of 979 patients, NAION occurred in 20 semaglutide users compared to 3 in the control group Cumulative NAION incidence over 36 months reached 8.9% for diabetic semaglutide users versus 1.8% for non-GLP-1 medications Weight loss patients showed 6.7% NAION incidence with semaglutide versus 0.8% without Manual chart review by neuro-ophthalmology specialists ensured diagnostic accuracy often lacking in larger database studies Risk persisted after controlling for known NAION risk factors including age, sex, hypertension, and sleep apnea The biological plausibility of semaglutide-induced NAION stems from multiple proposed mechanisms that researchers continue investigating